1-4 of 4
Peter Fong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Josep M. Piulats, Hardev S. Pandha, Daniel P. Petrylak, Fred Saad, Luis Miguel A. Aparicio, Shahneen K. Sandhu, Peter Fong, Silke Gillessen, Gary R. Hudes, Tao Wang, Judith Scranton, Michael N. Pollak
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1925–1934.
https://doi.org/10.1158/1078-0432.CCR-13-1869
Published: 31 March 2014
View article titled, Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer in another window
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Johann S. de Bono, Rebecca Kristeleit, Anthony Tolcher, Peter Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott, Amita Patnaik
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6663–6673.
https://doi.org/10.1158/1078-0432.CCR-08-0376
Published: 16 October 2008
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors in another window
Journal Articles

HDAC Inhibitors and Cardiac Safety

Rhoda Molife, Peter Fong, Michelle Scurr, Ian Judson, Stan Kaye, Johann de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 1068.
https://doi.org/10.1158/1078-0432.CCR-06-1715
Published: 08 February 2007
View article titled, HDAC Inhibitors and Cardiac Safety
Open the PDF for HDAC Inhibitors and Cardiac Safety in another window
Journal Articles

5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent

Mark J. McKeage, Peter Fong, Mark Jeffery, Bruce C. Baguley, Phil Kestell, Miroslav Ravic, Michael B. Jameson
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (6): 1776–1784.
https://doi.org/10.1158/1078-0432.CCR-05-1939
Published: 21 March 2006
View article titled, 5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent
Open the PDF for 5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent in another window